Pliant Therapeutics (PLRX) Share-based Compensation (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Share-based Compensation of $4.3 million for Q1 2026, down 52.27% year-over-year from $8.9 million in Q1 2025, and down 5.99% quarter-over-quarter from $4.5 million in Q4 2025.
Pliant Therapeutics (PLRX) Share-based Compensation (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Share-based Compensation for 8 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 52.27% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $21.6 million (down 5.62% YoY), while the FY2025 annual figure was $26.2 million, down 30.28% from the prior year.
- Share-based Compensation slipped to $4.3 million in Q1 2026 per PLRX's latest filing, from $4.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $23.7 million in Q1 2024 and bottomed at -$10.8 million in Q4 2022.
- Historically, Share-based Compensation has averaged $6.7 million across 5 years, with a median of $6.4 million in 2025.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 489.92% — and 2025, when it soared 1225.96%.
- Pliant Therapeutics' Share-based Compensation stood at -$10.8 million in 2022, then soared by 184.8% to $9.2 million in 2023, then retreated by 8.03% to $8.4 million in 2024, then tumbled by 46.24% to $4.5 million in 2025, then decreased by 5.99% to $4.3 million in 2026.
- Business Quant data shows PLRX's Share-based Compensation at $4.3 million in Q1 2026, $4.5 million in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | - |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | 4.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.19 Mn |
| Jun 30, 2026 | 4.19 Mn |
| Mar 31, 2026 | 4.25 Mn |
| Mar 31, 2026 | 4.25 Mn |
| Dec 31, 2025 | 4.53 Mn |
| Dec 31, 2025 | 4.53 Mn |
| Sep 30, 2025 | 6.42 Mn |
| Sep 30, 2025 | 6.42 Mn |
| Jun 30, 2025 | 6.38 Mn |
| Jun 30, 2025 | 6.38 Mn |
| Mar 31, 2025 | 8.91 Mn |
| Mar 31, 2025 | 8.91 Mn |
| Dec 31, 2024 | 8.42 Mn |
| Dec 31, 2024 | 8.42 Mn |
| Sep 30, 2024 | -570,000.00 |
| Sep 30, 2024 | -570,000.00 |
| Jun 30, 2024 | 6.10 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Mar 31, 2024 | 23.70 Mn |
| Mar 31, 2024 | 23.70 Mn |